BGPT: Paper Review: Drug safety assessment of oral formulations of ketoconazole

Explore by Goal

Quick Explanation Copied

Core finding (paper):

Oral ketoconazole is linked to clinically serious hepatotoxicity, endocrine effects (e.g., gynecomastia), and CYP3A4-mediated drug–drug interactions; the paper argues these risks drove major regulatory restrictions and reduced its role vs newer oral/targeted antifungals.

Evidence types synthesized include early clinical AEs, FAERS post-marketing reports, cohort data, and a meta-analysis of hepatotoxicity incidence.

Source: 10.1517/14740338.2015.983071.

Long Explanation

Drug safety assessment of oral formulations of ketoconazole — rigorous paper critique

Paper DOI: 10.1517/14740338.2015.983071 · Type: narrative expert safety review (not a primary trial)

Early clinical “common AEs” (percentages reported in the paper)

All values shown are those explicitly reported by the paper for oral ketoconazole early clinical data.

FAERS: ketoconazole-related cases by indication (paper-extracted table)

Counts are those explicitly listed in the paper’s FAERS indication table (n=64 cases total).

FAERS liver-related outcomes summarized by the paper

This visualization uses the review’s explicit summary counts: 34 cases with liver abnormalities, including 2 deaths and 1 transplant.

FAERS adverse reactions with >1% frequency (paper’s Table 2)

Reported as counts and percent in the review’s FAERS extraction (n provided in the paper’s table context).

Adverse reaction (as written)	Count	Percent
Liver damage*	27	10.5
Elevated liver enzymes	9	3.5
Jaundice	6	2.3
Hepatic failure	5	2.0
Hepatic necrosis	3	1.2
Vomiting	6	2.3
Nausea	5	2.0
Abdominal pain	3	1.2
Bloating	3	1.2
Drug interaction	7	2.7
Malaise	5	2.0
Rhabdomyolysis	5	2.0
Asthenia	4	1.6
Neurotoxicity	4	1.6
Erythema	4	1.6
Renal failure	3	1.2
Abasia	3	1.2
Fatigue	3	1.2
Headache	3	1.2
Myalgia	3	1.2
Oedema	3	1.2
Pancytopenia	3	1.2
Pruritis	3	1.2
Suicidal ideation	3	1.2
Swelling face	3	1.2
Urticaria	3	1.2

Mechanism-to-signal bridge (as argued in the paper)

A conceptual diagram tying ketoconazole’s CYP450/CYP3A inhibition and steroid pathway effects to hepatic injury, endocrine dysregulation, and interaction signals.

Skeptical scientific readout (known vs inferred vs uncertain)

What the paper makes fairly direct (higher confidence)

FAERS contains liver-abnormality signals and severe outcomes in the review’s extraction: among 64 FAERS cases, 34 included liver abnormalities; the paper reports 2 deaths and 1 liver transplant within those liver-abnormality cases.
Common early clinical AEs were reported at low single-digit percentages in the cited early clinical dataset (n=1361; nausea 3.0%, pruritus 1.7%, etc.).
Mechanistic plausibility is provided: the review emphasizes CYP450/CYP3A inhibition as a route to both hepatic risk and drug–drug interaction risk, and steroid pathway disruption as a route to endocrine dysregulation.

What requires caution (moderate confidence; causality limits)

FAERS does not establish causality. The paper explicitly notes that causality cannot be established because FAERS records lack sufficient detail. This means the correct epistemic status for FAERS is: signal detection, not confirmation of drug-caused liver injury in individuals.
Heterogeneity across underlying studies (case compilations, cohorts, RCTs, meta-analysis) can change what “incidence” means and how comparable it is across indications, patient risk profiles, and ascertainment methods. The paper itself includes such heterogeneous evidence types and uses them to argue global risk–benefit changes.
“Dose-independent” claims are hard to prove from observational and mixed-design data when dosing and duration can be confounded by indication severity, clinician selection, and reporting bias. The review states hepatotoxicity appears unrelated to dosage/duration, but the mechanistic substrate (CYP3A inhibition) suggests exposure-mediated risk could exist; resolving this tension would require high-quality dose–exposure linkage.

Regulatory inference: consistent with the safety signal, but still not the whole story

The paper reports that by 2013, oral ketoconazole was restricted or suspended in multiple jurisdictions due to risk–benefit considerations. Because regulatory actions integrate multiple evidence streams (including data not reproduced in the paper excerpt), the review’s regulatory framing supports the safety narrative, but it doesn’t automatically quantify absolute risk in modern populations.

Blind spots & disconfirming opportunities (what could change the conclusion)

Modern replication gap: if newer formulation/monitoring contexts and updated pharmacovigilance systems showed hepatotoxicity risk near zero after stratifying by age, comorbidity, polypharmacy, and baseline liver disease, then the risk framing could soften. The paper does not provide modern, fully stratified absolute risk estimates within a single cohesive dataset (it uses a synthesis).
Confounding in “idiosyncratic” DILI: DILI is described as unpredictable/idiosyncratic in the review; however, residual confounding (background liver disease, alcohol use, viral hepatitis status, concurrent hepatotoxins) can still masquerade as idiosyncrasy. Without detailed adjustment, the causal attribution can be overstated.

Most defensible bottom line (within evidence limits): The paper’s multi-source synthesis supports that oral ketoconazole carries a meaningful safety burden—especially for severe liver outcomes—and that this contributed to restricted regulatory positioning. Confidence is higher for “signal presence and mechanistic plausibility,” lower for “precise absolute risk by exposure/dose” due to causality and confounding limitations.

Author reviews (tap to compare perspectives)

Feedback:

Updated: April 12, 2026